Lung cancer screening

AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs

Retrieved on: 
Monday, October 12, 2020
Cancer screening, Radiation, Medical physics, Health effects of tobacco, Projectional radiography, Medicine, Electromagnetic radiation, Chest radiograph, Lung cancer screening, Radiology, National Lung Screening Trial, Radiography

SEOUL, South Korea, Oct. 12, 2020 /PRNewswire/ -- A recent study published in JAMA Network Open has shown that an AI algorithm trained to detect pulmonary nodules can improve lung cancer detection on chest radiographs.

Key Points: 
  • SEOUL, South Korea, Oct. 12, 2020 /PRNewswire/ -- A recent study published in JAMA Network Open has shown that an AI algorithm trained to detect pulmonary nodules can improve lung cancer detection on chest radiographs.
  • The joint research team analyzed 5,485 chest radiographs collected from participants in the National Lung Screening Trial (NLST) with Lunit INSIGHT CXR, an AI software for diagnosing chest x-rays.
  • It even had a higher sensitivity compared to NLST radiologists, implementing its possibility to help detect lung cancer when used as a second reader.
  • "Low-dose CT is recommended for lung cancer screening because the detection of chest radiographs is challenging for radiologists due to its projectional nature of radiography," explained Subba Digumarthy, the senior author of the study and an attending thoracic radiologist at MGH.

Thynk Health Solution Empowers MercyOne Des Moines to Grow Lung Screening Program

Retrieved on: 
Thursday, September 24, 2020
Medicine, MercyOne, Health, Lung cancer screening, Lung cancer, Clinical medicine, Screening

Empowered by Thynk Health's complete cancer screening and incidental finding management solution, MercyOne Des Moines is committed to improving lung cancer screening, detection, and patient care in Central Iowa.

Key Points: 
  • Empowered by Thynk Health's complete cancer screening and incidental finding management solution, MercyOne Des Moines is committed to improving lung cancer screening, detection, and patient care in Central Iowa.
  • Analyzing medical history and demographics, Thynk Health provides a complete patient profile, flagging patients at a higher risk of lung cancer.
  • Partnering with Thynk Health, MercyOne Des Moines plans to continue to make huge strides in fighting lung cancer in Central Iowa by raisingcommunity awareness for lung cancer screenings and increasing the numbers of incidental pulmonary nodules that are identified and referred to the pulmonary program.
  • "2019 was the most successful year the MercyOne Lung Cancer Screening, Pulmonary Nodule Program, and Lung Cancer Clinic has had.

CURE Media Group Announces Winners of the Inaugural 2020 Lung Cancer Heroes™ Awards

Retrieved on: 
Tuesday, September 22, 2020
Research, MEN, Pharmaceutical, Oncology, Consumer, Hospitals, Other Consumer, Science, Women, Nursing, Other Science, Health, Lung cancer, Neoplasms, Health, Clinical medicine, Lung Cancer Alliance, Lung cancer screening, Cancer research, Cancer

CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, is excited to announce the four winners of the inaugural 2020 Lung Cancer Heroes awards and the winner of the Lifetime Achievement award.

Key Points: 
  • CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, is excited to announce the four winners of the inaugural 2020 Lung Cancer Heroes awards and the winner of the Lifetime Achievement award.
  • The 2020 Lung Cancer Heroes winners are:
    Carolyn Baggett, RN, is a lung cancer screening program coordinator at Baptist MD Anderson Cancer Center (BMDACC) in Jacksonville, Florida.
  • In 2019, ALCF and the Lung Cancer Alliance merged, forming the GO2 Foundation for Lung Cancer, dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.
  • This event is supported and partner by Takeda and in partnership with The American Lung Association, GO2 Foundation for Lung Cancer, Lung Cancer Foundation of America, Lung Cancer Research Foundation, and LUNGevity.

Association of Community Cancer Centers Releases Lung Cancer Care Quality Improvement Model

Retrieved on: 
Friday, August 14, 2020
Child poverty, Federal assistance in the United States, Healthcare reform in the United States, Medicaid, Presidency of Lyndon B. Johnson, Lung cancer, Health, Lung Cancer Alliance, Lung cancer screening

ROCKVILLE, Md., Aug. 14, 2020 /PRNewswire/ -- The Association of Community Cancer Centers (ACCC) has just released a model framework for cancer care providers to use in improving care coordination for lung cancer patients covered by Medicaid.

Key Points: 
  • ROCKVILLE, Md., Aug. 14, 2020 /PRNewswire/ -- The Association of Community Cancer Centers (ACCC) has just released a model framework for cancer care providers to use in improving care coordination for lung cancer patients covered by Medicaid.
  • "Improving Care Coordination: A Model for Lung Cancer" is a first-of-its-kind quality improvement tool, now available to cancer programs and practices nationwide.
  • The Model is based upon an extensive research process and addresses lung cancer care for the patient populations enrolled in Medicaid, as these patients experience more negative lung cancer outcomes.
  • The Association of Community Cancer Centers is the leading education and advocacy organization of the cancer care community.

DGAP-News: New study published in the Journal of the National Cancer Institute concludes that Epi proColon(R) is the test of choice for the millions of individuals not willing to participate in FIT or colonoscopy screening

Retrieved on: 
Monday, August 10, 2020
Health, Articles, Medicine, Medical tests, Prevention, Medical terminology, Screening, Cancer, Lung cancer, Incremental cost-effectiveness ratio, Cancer screening, Lung cancer screening

Annual screening with Epi proColon had an incremental cost-effectiveness ratio (ICER) of $63,253 per QALYG.

Key Points: 
  • Annual screening with Epi proColon had an incremental cost-effectiveness ratio (ICER) of $63,253 per QALYG.
  • The JNCI publication analyzed the clinical effectiveness and performance of various screening strategies under five different scenarios:
    1.
  • Screening from age 50 through 75 years in an-average risk population, with perfect adherence to screening, diagnostic follow-up and surveillance recommendations.
  • Epi proLung(R), a blood-based test for lung cancer detection, and HCCBloodTest, a blood-based test for liver cancer detection in cirrohtic patients, have received CE mark in Europe.

Thynk Health Helps CHI Memorial Chattanooga Grow Mobile Lung Screening Program

Retrieved on: 
Tuesday, July 28, 2020
Medicine, Health, Lung cancer, Clinical medicine, Medical terminology, Health effects of tobacco, Prevention, Screening, Lung cancer screening, Cancer screening, Cancer

LEXINGTON, Ky., July 28, 2020 /PRNewswire/ --CHI Memorial Chattanooga innovates with Thynk Health's state-of-the-art screening technology and a mobile screening bus to bring lung screening to rural areas with high rates of at-risk patients and low rates of screening.

Key Points: 
  • LEXINGTON, Ky., July 28, 2020 /PRNewswire/ --CHI Memorial Chattanooga innovates with Thynk Health's state-of-the-art screening technology and a mobile screening bus to bring lung screening to rural areas with high rates of at-risk patients and low rates of screening.
  • Patients living in rural areas, like those served by CHI Memorial Chattanooga, experience additional challenges, including access to lung screening programs, and thus, screening implementation is some of the lowest at 1.6 percent.
  • Thynk Health was honored to partner with CHI Memorial on this effort, utilizing their powerful lung cancer screening solution to mine patient data and identify at-risk patients eligible for screening.
  • Monthly meetings with CHI Memorial Chattanooga and Thynk Health's experienced management team, mobile lung screening data, pulmonary and incidental findings, quality metrics, and effectiveness of screening sites were reviewed together.

bioAffinity Technologies Validation Trial for Non-Invasive Lung Cancer Test Results in High Sensitivity and Specificity

Retrieved on: 
Wednesday, June 10, 2020
Oncology, Health, Medical devices, Genetics, Managed care, Clinical trials, Biotechnology, Lung cancer, Medicine, Cancer, Cancer screening, Clinical medicine, Oncology, Lung cancer screening, Chemical pathology, Tuberculosis diagnosis

bioAffinity Technologies , a privately held biotech company, today announced its test validation trial for CyPath Lung resulted in specificity of 88% and sensitivity of 82%, similar to far more invasive procedures commonly used to diagnose lung cancer.

Key Points: 
  • bioAffinity Technologies , a privately held biotech company, today announced its test validation trial for CyPath Lung resulted in specificity of 88% and sensitivity of 82%, similar to far more invasive procedures commonly used to diagnose lung cancer.
  • CyPath Lung is a flow cytometric test to aid in the diagnosis of lung cancer.
  • The test validation trial compared sputum samples collected from individuals at high risk for lung cancer with sputum samples collected from lung cancer patients.
  • Our test for lung cancer has high specificity and sensitivity, in contrast to other tests that claim high sensitivity and very low specificity, or vice versa.

Annals of Family Medicine: Lung Cancer Screening Study Shows Low Complication Rates with the Support of Coordinated Multidisciplinary Care Team

Retrieved on: 
Tuesday, May 12, 2020
Medicine, Cancer screening, Lung cancer, Health, Medical terminology, RTT, Clinical medicine, Prevention, Lung cancer screening, Cancer, Screening, Cancer prevention

At the time, some leaders in the primary care community were not convinced that there was strong enough evidence in the initial trial to support routine screening.

Key Points: 
  • At the time, some leaders in the primary care community were not convinced that there was strong enough evidence in the initial trial to support routine screening.
  • A new lung cancer screening cohort study from the Providence Cancer Institute in Portland, Oregon, conducted at a large integrated health system suggests that lung cancer screening in primary care is feasible.
  • The study demonstrated low adverse event rates, and 70 percent of diagnosed lung cancer cases were detected at early stages in their development.
  • Therefore, family physicians should be engaged and equipped with guidance on best practices in lung cancer screenings and referrals.

Thrive Earlier Detection Announces Groundbreaking Clinical Data from the First Ever Interventional Study of a Blood-Based Test to Screen and Identify Multiple Types of Cancer

Retrieved on: 
Tuesday, April 28, 2020
Women, Biotechnology, Managed care, Oncology, Health, Medical devices, Consumer, Other Health, Medicine, Clinical medicine, RTT, Medical terminology, Medical tests, Cancer, Biopsy, Screening, Cancer screening, Lung cancer screening

The purpose was to identify multiple cancer types in asymptomatic individuals using an early version of CancerSEEK developed in 2016 (Thrives blood test).

Key Points: 
  • The purpose was to identify multiple cancer types in asymptomatic individuals using an early version of CancerSEEK developed in 2016 (Thrives blood test).
  • DETECT-A is the first study of a multi-cancer blood-based screening test to deliver results to physicians to manage patient care.
  • Thrive Earlier Detection Corp. is a healthcare company focused on incorporating earlier cancer detection into routine medical care to extend and save lives.
  • Thrive is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease.

Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 27, 2020
Health, Oncology, Medical devices, Health, Medicine, RTT, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Cancer, Medical test, Lung cancer screening

The "Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019" report has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of Lung Cancer Diagnostic Tests currently in pipeline stage.
  • The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development.
  • It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Lung Cancer Diagnostic Tests pipeline products.